CAJ | 학술논문

目的：探究紫杉醇脂质体联合顺铂治疗晚期食管癌的临床疗效及不良反应，为临床诊疗提供参考。方法：65例患者使用紫杉醇脂质体135m g/m2，dl，静脉滴注3h内完成，顺铂25mg/m2静脉滴注，d1～3，每周期21d，至少连用2周期，按RECIST1.0标准对治疗效果进行评价。结果：65例患者共进行212周期化疗，平均完成3.26周期，其中完全缓解6例(9.23%)，部分缓解24例(36.92%)，病变稳定15例(23.08%)，疾病进展20例(30.77%)，总有效率为46.15%，临床受益率为(69.23%)；1年生存率为83.07%，2年生存率为52.31%，疾病中位进展时间6月(95%C I：5.01～6.57)；不良反应主要表现在骨髓抑制和消化道反应方面，无化疗相关性死亡。结论：紫杉醇脂质体联合顺铂治疗晚期食管癌临床疗效好，毒性可以耐受，值得临床推广。
목적：탐구자삼순지질체연합순박치료만기식관암적림상료효급불량반응，위림상진료제공삼고。방법：65례환자사용자삼순지질체135m g/m2，dl，정맥적주3h내완성，순박25mg/m2정맥적주，d1～3，매주기21d，지소련용2주기，안RECIST1.0표준대치료효과진행평개。결과：65례환자공진행212주기화료，평균완성3.26주기，기중완전완해6례(9.23%)，부분완해24례(36.92%)，병변은정15례(23.08%)，질병진전20례(30.77%)，총유효솔위46.15%，림상수익솔위(69.23%)；1년생존솔위83.07%，2년생존솔위52.31%，질병중위진전시간6월(95%C I：5.01～6.57)；불량반응주요표현재골수억제화소화도반응방면，무화료상관성사망。결론：자삼순지질체연합순박치료만기식관암림상료효호，독성가이내수，치득림상추엄。
Objective: To paclitaxel liposome combined with cisplatin treatment efficacy and adverse reactions were analyzed with advanced esophageal cancer, discuss treatment options with advanced esophageal cancer. Methods: 65 cases of advanced esophageal cancer in our hospital were randomly divided into observation group and control group 30 cases, 35 cases observation group liposomal paclitaxel plus cisplatin regimen, the control group, paclitaxel and cisplatin chemotherapy, 21 days for a cycle, once every two cycles evaluated. Results: There are two sets of objects to observe the effect of the recent intervention was no significant difference in overal efficiency (P> 0.05); groups observed object in leukopenia, nausea, vomiting, differences in terms of hair loss, muscle pain, skin rash was statistical y significant (P <0.05). Conclusion: The short-term effect of paclitaxel plus cisplatin liposomes with paclitaxel and cisplatin similar, but smal er former adverse reactions in patients.